170 related articles for article (PubMed ID: 2252812)
21. Prostaglandin E2 administered by subcutaneous pellets causes local inflammation and systemic bone loss: a model for inflammation-induced bone disease.
Desimone DP; Greene VS; Hannon KS; Turner RT; Bell NH
J Bone Miner Res; 1993 May; 8(5):625-34. PubMed ID: 8511990
[TBL] [Abstract][Full Text] [Related]
22. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats.
Lauritzen DB; Balena R; Shea M; Seedor JG; Markatos A; Le HM; Toolan BC; Myers ER; Rodan GA; Hayes WC
J Bone Miner Res; 1993 Jul; 8(7):871-9. PubMed ID: 8352069
[TBL] [Abstract][Full Text] [Related]
23. Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys.
Boyce RW; Niu QT; Ominsky MS
Bone; 2017 Aug; 101():77-87. PubMed ID: 28428078
[TBL] [Abstract][Full Text] [Related]
24. Lumbar vertebral cancellous bone is capable of responding to PGE2 treatment by stimulating both modeling and remodeling-dependent bone gain in aged male rats.
Zhou H; Ma YF; Yao W; Cui L; Setterberg R; Liang CT; Jee WS
Calcif Tissue Int; 2001 Mar; 68(3):179-84. PubMed ID: 11351502
[TBL] [Abstract][Full Text] [Related]
25. Partial loss of anabolic effect of prostaglandin E2 on bone after its withdrawal in rats.
Ke HZ; Li XJ; Jee WS
Bone; 1991; 12(3):173-83. PubMed ID: 1910959
[TBL] [Abstract][Full Text] [Related]
26. Early effects of prostaglandin E2 on bone formation and resorption in different bone sites of rats.
Lin CH; Jee WS; Ma YF; Setterberg RB
Bone; 1995 Oct; 17(4 Suppl):255S-259S. PubMed ID: 8579925
[TBL] [Abstract][Full Text] [Related]
27. The effect of androstenedione/estrone supplementation on cortical and cancellous bone in the young intact female monkey: a model for the effects of polycystic ovarian disease on the skeleton?
Lundon KM; Jayo MJ; Register TC; Dumitriu M; Grynpas MD
Osteoporos Int; 2000; 11(9):778-89. PubMed ID: 11210841
[TBL] [Abstract][Full Text] [Related]
28. Effects of prostaglandin E2 on production of new cancellous bone in the axial skeleton of ovariectomized rats.
Mori S; Jee WS; Li XJ; Chan S; Kimmel DB
Bone; 1990; 11(2):103-13. PubMed ID: 2192750
[TBL] [Abstract][Full Text] [Related]
29. Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats.
Iwamoto J; Yeh JK; Takeda T
J Bone Miner Res; 2003 Apr; 18(4):776-83. PubMed ID: 12674339
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats.
Li M; Jee WS; Ke HZ; Tang LY; Ma YF; Liang XG; Setterberg RB
J Bone Miner Res; 1995 Jan; 10(1):66-73. PubMed ID: 7747632
[TBL] [Abstract][Full Text] [Related]
31. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
Christiansen P
APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of vitamin K2 and prostaglandin E2 on cancellous bone mass in hypophysectomized young rats.
Iwamoto J; Takeda T; Sato Y; Yeh JK
Calcif Tissue Int; 2006 Nov; 79(5):318-25. PubMed ID: 17048065
[TBL] [Abstract][Full Text] [Related]
33. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.
Yao W; Tian XY; Chen J; Setterberg RB; Lundy MW; Chmielzwski P; Froman CA; Jee WS
J Musculoskelet Neuronal Interact; 2007; 7(2):119-30. PubMed ID: 17627081
[TBL] [Abstract][Full Text] [Related]
34. Effects of alfacalcidol on cancellous and cortical bone mass in rats treated with glucocorticoid: a bone histomorphometry study.
Iwamoto J; Seki A; Takeda T; Yamada H; Sato Y; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2007 Jun; 53(3):191-7. PubMed ID: 17874822
[TBL] [Abstract][Full Text] [Related]
35. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
Seeman E
Osteoporos Int; 2003; 14 Suppl 3():S2-8. PubMed ID: 12730770
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae.
Suponitzky I; Weinreb M
J Endocrinol; 1998 Jan; 156(1):51-7. PubMed ID: 9496233
[TBL] [Abstract][Full Text] [Related]
37. Effects of daily administration of prostaglandin E2 and its withdrawal on the lumbar vertebral bodies in male rats.
Ke HZ; Jee WS
Anat Rec; 1992 Oct; 234(2):172-82. PubMed ID: 1416104
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
Exp Anim; 2006 Jul; 55(4):357-67. PubMed ID: 16880683
[TBL] [Abstract][Full Text] [Related]
39. Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):1-8. PubMed ID: 16637224
[TBL] [Abstract][Full Text] [Related]
40. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA
Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
